Heart Failure/Transplantation
Cohort Study | Albuminuria as a marker of systemic congestion in patients with heart failure.
7 Oct, 2022 | 14:19h | UTC
Brief Review | How do we maximize diuresis in acute decompensated heart failure?
5 Oct, 2022 | 13:51h | UTC
Cohort Study | Cardiovascular MRI phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis.
30 Sep, 2022 | 12:39h | UTCCardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
Cardiovascular magnetic resonance phenotypes could be used to optimize clinical decision-making for treatment options, such as implantable cardioverter-defibrillators, and thus improve outcomes in patients with suspected cardiac #sarcoidosis. https://t.co/6hlpPFd7cd #Research
— JAMA Cardiology (@JAMACardio) September 14, 2022
ACEP Clinical Policy | Critical issues in the management of patients presenting to the ED with acute heart failure syndromes.
27 Sep, 2022 | 13:20h | UTC
Consensus Paper | Renal effects of guideline-directed medical therapies in heart failure.
27 Sep, 2022 | 13:13h | UTC
Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy.
26 Sep, 2022 | 11:57h | UTC
Commentary on Twitter
Is it possible to predict which pts w/ dilated cardiomyopathy/left ventricular dysfunction will have an assoc. predisposition on genetic testing?
Via the Madrid Score, Drs. @LuisEscobarL, @dr_pavia, & colleagues work to answer this question in #JACC: https://t.co/WDn8jA29aY pic.twitter.com/u0T9FffOwi
— JACC Journals (@JACCJournals) September 13, 2022
M-A | Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction.
22 Sep, 2022 | 13:05h | UTCRelated M-A: SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (link to abstract – $ for full-text)
A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.
20 Sep, 2022 | 13:16h | UTCA Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction – JAMA Cardiology (link to abstract – $ for full-text)
Commentary on Twitter
This cohort study found that a simple 6 variable clinical score may be used to guide use of PYP and increase recognition of cardiomyopathy (ATTR-CM) among patients with HFpEF in the community. https://t.co/2fzCZf97Mp #Research
— JAMA Cardiology (@JAMACardio) September 7, 2022
Guideline Synopsis | AHA/ACC Guideline for the management of heart failure.
16 Sep, 2022 | 13:01h | UTCManagement of Heart Failure – JAMA (free for a limited period)
Original Article: #ACC22 – 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.
Retrospective Cohort Study | Natural history of MYH7-related dilated cardiomyopathy.
14 Sep, 2022 | 13:06h | UTC
Five-year outcomes in patients with fully magnetically levitated vs. axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.
11 Sep, 2022 | 22:43h | UTCFive-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial – JAMA (free for a limited period)
Commentary on Twitter
Among patients with advanced #heartfailure, receipt of a fully magnetically levitated centrifugal-flow LVAD vs axial-flow LVAD was associated with a better composite outcome and higher likelihood of overall survival at 5 years. #Research https://t.co/S0KdHp0tAO
— JAMA (@JAMA_current) September 8, 2022
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.
29 Aug, 2022 | 12:38h | UTCPercutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology
Commentary on Twitter
REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN
— NEJM (@NEJM) August 27, 2022
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
29 Aug, 2022 | 12:25h | UTCAcetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology
Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology
Commentary on Twitter
https://twitter.com/NEJM/status/1563421082505588738
Secondary analysis of a RCT | Effects of Empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.
26 Aug, 2022 | 13:24h | UTCCommentary: Empagliflozin Offers Clinical Benefit in Heart Failure – HealthDay
Original Study: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial – Nature Medicine
Observational study suggests Hydroxychloroquine is associated with increased risk of cardiovascular events compared to Methotrexate in patients with heart failure.
25 Aug, 2022 | 11:56h | UTCCardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Editorial: Hydroxychloroquine: Heart-Throb No More? – Journal of the American College of Cardiology
Commentary: Caution needed with hydroxychloroquine use in older RA patients with heart failure – medwire News
Left ventricular assist devices: a primer for the non-mechanical circulatory support provider.
17 Aug, 2022 | 13:51h | UTC
RCT | Sustained-release ivabradine hemisulfate in patients with systolic heart failure.
16 Aug, 2022 | 13:01h | UTC
RCT | Omecamtiv Mecarbil does not improve exercise capacity in chronic heart failure with reduced ejection fraction.
15 Aug, 2022 | 12:07h | UTCEffect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Author Interview: Can Omecamtiv Mecarbil Improve Peak Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)? – JAMA
Commentaries:
Omecamtiv Mecarbil Fails to Improve Exercise Capacity in HFrEF – Medscape (free registration required)
Commentary on Twitter
#OriginalInvestigation: Multicenter randomized clinical trial found that, in patients with chronic #HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. @GLewisCardiol https://t.co/f27Y0oya6S
— JAMA (@JAMA_current) July 20, 2022
Cohort Study | Age at menopause and risk of heart failure and atrial fibrillation.
5 Aug, 2022 | 14:38h | UTCAge at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study – European Heart Journal (link to abstract – $ for full-text)
Editorial: Premature menopause and cardiovascular disease: can we blame estrogen? – European Heart Journal
News Release: Premature menopause is associated with increased risk of heart problems – European Society of Cardiology
RCT | Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction.
3 Aug, 2022 | 14:06h | UTC
Commentary on Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
Review | Management of heart failure in patients with chronic kidney disease.
1 Aug, 2022 | 11:59h | UTCManagement of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review